Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop
Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop
PR Newswire
SAN FRANCISCO, Oct. 7, 2026
SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Aquestive Therapeutics, Inc. (Nasdaq: AQST) investors that the firm is investigating potential legal claims arising from alleged false and misleading statements about the company's drug candidate Anaphylm. Current shareholders are encouraged to contact the firm here: https://www.classactionlawyers.com/aquestive.
On January 9, 2026, Aquestive announced that the FDA had identified deficiencies in its New Drug Application for Anaphylm that precluded discussions of labeling and post-marketing commitments. Following this news, Aquestive's stock price declined 37%. According to a securities class action complaint, between June 2025 and January 2026, Aquestive misled investors about the prospects for FDA approval of Anaphylm, including by representing that approval remained on track for the January 31, 2026 target action date.
We are investigating potential wrongdoing by Aquestive's directors and officers in connection with these allegations.
If you own Aquestive stock, you may have legal options. Visit https://www.classactionlawyers.com/aquestive to learn more.
About Schubert Jonckheer & Kolbe LLP
Schubert Jonckheer & Kolbe represents consumers in class actions and shareholders in derivative actions against corporate officers and directors. The firm is based in San Francisco and, with the help of co-counsel, litigates cases nationwide.
Contact
Dustin L. Schubert
dschubert@sjk.law
Tel: 415-788-4220
SOURCE Schubert Jonckheer & Kolbe LLP
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
3 Stocks to Invest In With More Room to Run
United States